The developing landscape of diabetes treatment is witnessing a significant shift, driven by innovative incretin-based therapies. Presently, semaglutide has achieved considerable recognition, but rival medications like tirzepatide, retatrutide, and cagrilintide are set to reshape the outlook. Tirz